Abstract
Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. A mAb that selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8þ T cells in ex vivo primary tumors.
Cite
CITATION STYLE
APA
de Miguel, D., & Pardo, J. (2021). TRAIL and cancer immunotherapy: Take a walk on the short side. Clinical Cancer Research, 26(21), 5546–5548. https://doi.org/10.1158/1078-0432.CCR-20-2751
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free